Corning Jerry Pharmaceutical-B (09966): The IND application for a phase II clinical trial of JSKN033 was officially accepted by the CDE

Zhitongcaijing · 2d ago

Zhitong Finance App News, Corning Jerry Pharmaceutical-B (09966) announced that a phase II clinical trial (IND) of JSKN033 (a high-concentration subcutaneous combination preparation composed of an anti-human epidermal growth factor receptor 2 (HER2) bispecific antibody conjugate drug (ADC (s)) and a programmed death ligand 1 (PDL1) immune checkpoint inhibitor) combined with platinum chemotherapy with or without bevacizumab for first-line treatment of advanced cervical cancer (IND) has been applied for Received a national drug JSKN033 The Drug Evaluation Center (CDE) of the Supervisory Authority officially accepted it.

JSKN033-202 is an open, multicenter, phase II clinical trial to evaluate the safety, efficacy and pharmacokinetic/pharmacodynamic characteristics of JSKN033 combined with platinum chemotherapy in first-line treatment with or without bevacizumab in patients with advanced cervical cancer. All patients will receive JSKN033 with cisplatin or carboplatin with or without bevacizumab. The choice of platinum drugs and whether to use bevacizumab in combination will be determined by the researchers based on the patient's specific circumstances.